


**Westminster Health Forum Keynote Seminar:
The future of pharmaceutical pricing and access to medicines**

Timing: Morning, Thursday, 25th April 2019

Venue: Central London



**WESTMINSTER
HEALTH FORUM**

Draft agenda subject to change

- 8.30 - 9.00 Registration and coffee
- 9.00 - 9.05 **Chair's opening remarks**
Baroness Jolly, Liberal Democrat Lords Spokesperson for Health
- 9.05 - 9.30 **The Voluntary Scheme for Branded Medicines Pricing and Access - key aims**
Andina Ward, Deputy Director for Medicines Pricing, Department of Health and Social Care
Questions and comments from the floor
- 9.30 - 9.40 **The role of NHS England in increasing access: supporting innovation, engaging with patients and industry, and improving adoption**
Senior representative, NHS
- 9.40 - 9.55 **'Industry Perspective on the Voluntary Scheme for Branded Medicines Pricing and Access'**
Paul Catchpole, Director of Value and Access, Association of the British Pharmaceutical Industry
David Watson, Director of Pricing and PPRS, Association of the British Pharmaceutical Industry
- 9.55 - 10.10 Questions and comments from the floor
- 10.10 - 10.55 **Bringing new products to the market - price control, the impact of the Accelerated Access Collaborative and preparing for Brexit**
Paul Ranson, Consultant, Morgan Lewis
Keith Jordan, Communications, Policy and Access Director, Roche
Senior speaker confirmed from **Roboleo & Co**
Senior representative, NHS
Questions and comments from the floor
- 10.55 - 11.00 **Chair's closing remarks**
Baroness Jolly, Liberal Democrat Lords Spokesperson for Health
- 11.00 - 11.25 Coffee
- 11.25 - 11.30 **Chair's opening remarks**
Anne Marie Morris MP, Chair, All-Party Parliamentary Group on Access to Medicines and Medical Devices
- 11.30 - 12.10 **Priorities for improving access to medicines in the NHS**

Meeting patient choice - and implications for cost
Nick Medhurst, Head of Policy and Public Affairs, Cystic Fibrosis Trust

Value-based pricing, reimbursement and supply chains - challenges for industry
Dr Stuart Dollow, Founder, Vermilion Life Sciences

Improving efficiency in prescribing - the impact of Regional Medicine Optimisation Committees
Senior representative, commissioning

Emerging forms of competition - evaluating the uptake of biosimilars
Professor Mike Hannay, Chief Executive, East Midlands Academic Health Science Network
- 12.10 - 12.30 Questions and comments from the floor
- 12.30 - 12.55 **Next steps in assessing cost effectiveness - priorities for NICE**
Meindert Boysen, Director, Centre for Health Technology Evaluation, NICE
Questions and comments from the floor
- 12.55 - 13.00 **Chair's and Westminster Health Forum closing remarks**
Anne Marie Morris MP, Chair, All-Party Parliamentary Group on Access to Medicines and Medical Devices
Michael Ryan, Deputy Editor, Westminster Health Forum